Objective Studies investigating the association between matrix metalloproteinase-1 (MMP1) gene promoter 1607–base pair (bp) polymorphism and ovarian cancer risk have yielded conflicting results.
Methods We therefore carried out a meta-analysis of 754 ovarian cancer cases and 1184 controls from 5 published case-control studies. The strength of the association between MMP1 1607-bp polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs).
Results The results suggest that no statistically significant associations exist between MMP1 1607-bp polymorphisms and ovarian cancer risk in all 4 genetic models (2G2G vs 1G1G: OR, 1.08; 95% CI, 0.81–1.43; P = 0.23; 1G2G vs 1G1G: OR, 1.06; 95% CI, 0.82–1.36; P = 0.15; 1G2G + 2G2G vs 1G1G: OR, 1.05; 95% CI, 0.83–1.34; P = 0.16; 2G2G vs 1G1G + 1G2G: OR, 0.98; 95% CI, 0.80–1.20; P = 0.84).
Conclusions In summary, this meta-analysis showed that the MMP1 1607-bp polymorphism is not associated with ovarian cancer risk.
- Ovarian cancer
- Matrix metalloproteinase-1
- Gene polymorphism
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This work was supported by the National High Technology Research and Development Program (“863”Program) of China (2014AA020605), National Natural Science Foundation of China (81272857).
The authors declare no conflicts of interest.